CJC-1295
NOT FDA APPROVEDGrowth-hormone-releasing hormone analog
Also known as: CJC-1295 DAC, Mod GRF 1-29 (no-DAC variant)
Not FDA approved. Sold as a research chemical, labelled not for human consumption.
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 1 registered study on ClinicalTrials.gov, most advanced Phase 2
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: small human studies show it raises GH and IGF-1. NOT proven: real-world functional benefits (strength, fat loss, anti-aging). Never developed into an approved product.
What it is
A GHRH analog that stimulates the pituitary to release growth hormone. The DAC version binds albumin to extend its action.
What the research says
Small early human studies showed raised GH/IGF-1. Not developed into an approved product.
Reported user goals. Not established in controlled trials.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing CJC-1295 in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.
Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where CJC-1295 is the intervention being tested.
FDA recalls & enforcement
CJC-1295 has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- No long-term human safety data.
- Same theoretical GH/IGF-1 growth-signalling concerns.
- Content and variant (DAC vs no-DAC) are frequently mislabelled.
Doses reported in studies & protocols
Community protocols vary by variant. No established clinical dose. This is not a recommendation.
Purity reality
A COA is the only way to confirm content and variant.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.